|
|
|
ix | |
| Foreword |
|
xvii | |
|
|
| Foreword |
|
xix | |
|
|
| Preface |
|
xxi | |
| Acknowledgments |
|
xxiii | |
| Color plates |
|
xxxii | |
|
Part I Systemic and Endoluminal Therapy |
|
|
|
1 An overview of hemostasis and thrombosis |
|
|
1 | (30) |
|
|
|
|
|
|
|
|
|
|
|
|
|
2 Principles of antiplatelet therapy |
|
|
31 | (10) |
|
|
|
|
|
|
|
3 Glycoprotein IIb/IIIa inhibitors |
|
|
41 | (18) |
|
|
|
4 Adenosine diphosphate receptor inhibitors |
|
|
59 | (10) |
|
|
|
5 Phosphodiesterase inhibitors: dipyridamole and cilostazol |
|
|
69 | (10) |
|
|
|
6 Heparin, low molecular weight heparin |
|
|
79 | (6) |
|
|
|
|
|
7 Direct thrombin inhibition in percutaneous coronary intervention |
|
|
85 | (8) |
|
|
|
|
|
|
|
8 Clinical application of direct antithrombin inhibitors in acute coronary syndrome |
|
|
93 | (16) |
|
|
|
|
|
|
|
|
|
9 Oral antithrombin drugs |
|
|
109 | (10) |
|
|
|
10 Rationale for direct factor Xa inhibitors in acute coronary syndromes |
|
|
119 | (8) |
|
|
|
|
|
11 Combined anticoagulant and antiplatelet therapy |
|
|
127 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
135 | (4) |
|
|
|
13 Resistance to antiplatelet drugs |
|
|
139 | (16) |
|
|
|
|
|
|
|
155 | (16) |
|
|
|
|
|
15 Improving the diagnosis and management of high blood pressure in the cardiac patient |
|
|
171 | (6) |
|
|
|
16 Homocysteine regulators |
|
|
177 | (8) |
|
|
|
|
|
17 Role of systemic antirestenotic drugs and results of current clinical trials |
|
|
185 | (10) |
|
|
|
18 Role of systemic antineoplastic drugs in the treatment of restenosis after percutaneous stent implantation |
|
|
195 | (16) |
|
|
|
|
|
211 | (30) |
|
|
|
20 Iron chelation: deferoxamine and beyond |
|
|
241 | (8) |
|
|
|
|
|
|
21 Stent-mediated local drug delivery |
|
|
249 | (18) |
|
|
|
|
|
|
|
22 The application of controlled drug delivery principles to the development of drug-eluting stents |
|
|
267 | (12) |
|
|
|
|
|
|
|
|
|
279 | (10) |
|
|
|
|
|
|
|
24 Polymers and drug-eluting stents |
|
|
289 | (10) |
|
|
|
|
|
25 Utilization of antiproliferative and antimigratory compounds for the prevention of restenosis |
|
|
299 | (16) |
|
|
|
|
|
26 Anti-inflammatory drugs, sirolimus, and inhibition of target of rapamycin and its effect on vascular diseases |
|
|
315 | (10) |
|
|
|
27 Anti-migratory drugs and mechanisms of action |
|
|
325 | (14) |
|
|
|
|
|
|
|
28 Antiangiogenetic drugs---mechanisms of action |
|
|
339 | (8) |
|
|
|
|
|
29 Vasculoprotective approach for restenosis |
|
|
347 | (8) |
|
|
|
|
|
|
|
|
|
30 Vascular endothelial growth factor |
|
|
355 | (8) |
|
|
|
|
|
31 Gene therapy: role in myocardial protection |
|
|
363 | (8) |
|
|
|
|
|
|
|
|
|
371 | (10) |
|
|
|
|
|
33 Principles of photodynamic treatment |
|
|
381 | (12) |
|
|
|
|
|
Part III Cell Therapy and Therapeutic Angiogenesis |
|
|
|
34 Angiogenesis and myogenesis |
|
|
393 | (14) |
|
|
|
|
|
407 | (12) |
|
|
|
|
|
|
|
36 Cell transplantation for cardiovascular repair |
|
|
419 | (20) |
|
|
|
|
|
|
|
37 Clinical trials in cellular therapy |
|
|
439 | (12) |
|
|
|
|
|
|
|
Part IV Adjunctive Pharmacotherapy |
|
|
|
38 The heart failure patient |
|
|
451 | (14) |
|
|
|
|
|
39 The acute coronary syndrome patient |
|
|
465 | (8) |
|
|
|
40 Cardiovascular interventional pharmacology in the diabetic patient |
|
|
473 | (10) |
|
|
|
|
|
41 Atrial fibrillation during catheterization |
|
|
483 | (10) |
|
|
|
|
|
|
|
42 Contrast-induced nephropathy after percutaneous coronary interventions |
|
|
493 | (10) |
|
|
|
|
|
503 | (12) |
|
|
|
44 Peripheral arterial disease |
|
|
515 | (10) |
|
|
|
|
|
45 Pharmacotherapy peri-percutaneous coronary intervention |
|
|
525 | (12) |
|
|
|
|
|
|
|
46 Pharmacologic management of patients with CTO interventions |
|
|
537 | (6) |
|
|
|
47 Newer pharmacologic approaches targeting receptors and genes |
|
|
543 | (12) |
|
|
|
|
|
|
|
Part V Noncoronary Interventions |
|
|
|
48 Carotid artery stenting |
|
|
555 | (14) |
|
|
|
|
|
|
|
|
|
49 Anticoagulants in peripheral vascular interventions |
|
|
569 | (14) |
|
|
|
|
|
|
|
|
|
583 | (10) |
|
|
|
|
|
51 Interventions for structural heart disease |
|
|
593 | (10) |
|
|
|
|
|
|
|
52 Pharmacological use of ethanol for myocardial septal ablation |
|
|
603 | (10) |
|
|
|
|
|
|
| Epilogue: Anticoagulant management of patients undergoing interventional procedures |
|
613 | (6) |
|
|
| Appendix A |
|
619 | (4) |
| Appendix B |
|
623 | (4) |
| Index |
|
627 | |
